Beijing Immunochina Medical Science & Technology Co., Ltd.

This early-phase study tests a new treatment called IM96 CAR-T cells for people with advanced stomach or esophageal junction cancer that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to better target and attack cancer cells. The…